Topic
pharmaceutical regulation
6 stories related to this topic, newest first.
ndtv.combusiness24 days ago
U.S. Administration Proposes Medicare Drug Negotiation Rule Changes
The Trump administration proposed altering a policy that prevents drugmakers from avoiding Medicare price negotiation by adding active ingredients to existing drugs. The change is part of an annual rule governing selection of the next 20 drugs and biologics for negotiation.
nypost.comworld31 days ago
Federal Courts Convict Operators of Unlicensed Patent Medicine Shops as PSN Calls for Stricter Enforcement
Two May and June 2026 rulings convicted operators of unlicensed drug outlets. The Pharmaceutical Society of Nigeria called the decisions historic.
Statscience54 days ago
Acting Director of FDA Drug Center Tracy Beth Høeg Leaves Agency
Tracy Beth Høeg, acting director of the Food and Drug Administration’s Center for Drug Evaluation and Research, is departing the agency. The departure comes days after Commissioner Marty Makary submitted his resignation. Michael Davis, the center’s current deputy director, will a…
thebalitimes.comworld55 days ago
FDA Rejects Replimune Melanoma Treatment RP1
The Food and Drug Administration declined to approve RP1, a genetically engineered treatment for melanoma developed by Replimune. One-third of participants in a 140-patient clinical trial saw their tumors shrink or disappear. The agency cited the lack of a control arm comparing t…
manilatimes.netpolitics63 days ago
Made-in-China Agrees to Stop Selling GLP-1 Compounds in U.S., Pays $30,000 Penalty to Connecticut
The international online platform agreed to halt all sales of GLP-1 medications to U.S. customers and pay a suspended $300,000 penalty. Connecticut Attorney General William Tong said the drugs contained impurities and inconsistent active ingredients with no generic versions legal…
AB
Adrian McArdle, M.B, B.Ch., Kshemendra Senarath-Yapa, M.B.B.Chir., Graham G. Walmsley, B.S., Michael Hu, M.D., M.P.H., David A. Atashroo, M.D.,Ruth Tevlin, M.B., B.Ch.,Elizabeth Zielins, M.D.,Geoffrey C. Gurtner, M.D., Derrick C. Wan, M.D., and Michael T. Longaker, M.D., F.A.C.S. / Wikimedia (CC BY-SA 4.0)finance84 days ago
Nkarta Receives Approval for Outpatient Dosing in Lupus Nephritis Trial
Nkarta announced that regulators have approved a protocol change allowing outpatient dosing of its NKX019 therapy in lupus nephritis trials, reducing patient monitoring time to two hours. Following this update, Nkarta's stock price increased by approximately 13%.